Annovis Bio CEO: Buntanetap Prepares for Third Quarter Data Readout
Annovis Bio expects the final patient to complete the 6-month Phase 3 DUET-AD trial in December 2026, with data readout scheduled for March 2027. The company raised $21.0 million in an underwritten public offering to advance buntanetap toward FDA filing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed